Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2614

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2614
---
 and other available products for licensing by other companies. Collaborations are complex and time-consuming to negotiate
and document. In addition, there have been a significant number of recent business combinations among large biopharmaceutical companies
that have resulted in a reduced number of potential future collaborators. Our ability to reach a definitive agreement for a collaboration
will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of
the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. If we are unable to reach agreements
with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate,
reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce
the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities
at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need
to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all. If we fail to
enter into future collaborations or do not have sufficient funds or expertise to undertake the necessary development and commercialization
activities, we may not be able to further develop our product candidates, bring them to market and generate revenue from sales of drugs
or continue to develop our technology, and our business may be materially and adversely affected. Even if we are successful in our efforts
to establish new strategic collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain
such strategic collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product
are disappointing. Any delay in entering into new strategic collaboration agreements related to our product candidates could delay the
development and commercialization of our product candidates and reduce their competitiveness even if they reach the market.

94

Risks
Related to Our Intellectual Property

Our
success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights
and technology, and we may not be able to ensure their protection.

Our
business will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies
and our product candidates, their respective components, synthetic intermediates, formulations, combination therapies, methods used to
manufacture them and methods